This week Neurology News Network covered:

- Long-term trial evaluating fingolimod's ability to preserve cognition in patients with MS ([ Ссылка ])
- Discontinuation of Alexion Pharmaceuticals' phase 3 trial of ravulizumab in ALS ([ Ссылка ])
- Full results of ADVANCE, a pivotal study evaluating atogepant as a preventive treatment ([ Ссылка ])

свернуть